Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News BMS presents Orencia analyses for rheumatoid arthritis

BMS presents Orencia analyses for rheumatoid arthritis

13th June 2008

Bristol-Myers Squibb (BMS) has announced the publication of the results of radiographic analyses for the Aim study of Orencia (abatacept) in patients with moderate-to-severe rheumatoid arthritis.

The analyses showed that the compound provided patients with an increasing degree of inhibition of structural damage over three years of treatment in patients who had previously had an inadequate response to treatment with methotrexate (MTX).

BMS told the annual congress of the European League Against Rheumatism the durability of this effect was maintained throughout the three-year study period, with an increasing inhibition of joint erosion and joint space narrowing with Orencia plus MTX.

The Genant-modified Sharp scoring method was used in the trial for the radiographic assessment of joint space narrowing score, erosion score and total score.

Joel Kremer, Pfaff family professor of medicine at Albany Medical College, said that rheumatoid arthritis is a serious and chronic condition that gets worse over time.

“Identifying long-term therapies that not only inhibit radiographic progression of the disease, but do so over an extended period of time, is critical to effectively treat this patient population,” he added.

In April 2008, BMS announced that Orencia had been approved by the US Food and Drug Administration as a treatment to reduce the signs and symptoms of juvenile idiopathic arthritis.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.